Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden

Figure 1 Summary findings of one-way sensitivity analyses for Sweden. A: One-way sensitivity analyses in midgut neuroendocrine tumors; B: One-way sensitivity analyses in pancreatic neuroendocrine tumors. QALY: Quality-adjusted life year; PPS: Post-progression survival; PFS: Progression-free survival; GI-NETs: Gastrointestinal-neuroendocrine tumors; LAR: Long-acting release; CT: Computed tomography; MRI: Magnetic resonance imaging; P-NET: Pancreatic-neuroendocrine tumor; AE: Adverse event.

Figure 2 Summary findings of one-way sensitivity analyses for Norway. A: One-way sensitivity analyses in midgut neuroendocrine tumors; B: One-way sensitivity analyses in pancreatic neuroendocrine tumors. QALY: Quality-adjusted life year; PPS: Post-progression survival; PFS: Progression-free survival; GI-NETs: Gastrointestinal-neuroendocrine tumors; LAR: Long-acting release; CT: Computed tomography; MRI: Magnetic resonance imaging; P-NET: Pancreatic-neuroendocrine tumor; AE: Adverse event.